Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Manufacturing

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part I)

Discover how emerging technologies and expert insights are shaping the future of pharma manufacturing
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

A pharmacodynamic analysis platform for targeted protein degrader drugs

Targeted protein degraders (TPDs) are an emerging class of therapeutics that harness a cell’s built-in waste removal process to eliminate disease-causing proteins
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Manufacturing

Indena showcases expanded capabilities, innovative APIs and ADC partnership at CPHI 2025

Indena, a global leader in plant-derived active pharmaceutical ingredients (APIs), will present its latest technological and manufacturing advances at CPHI 2025 (Frankfurt, 28–30 October)
Manufacturing

SGD Pharma presents new innovations at CPHI Frankfurt 2025

SGD Pharma, a global leader in pharmaceutical glass primary packaging solutions, will showcase its enhanced portfolio of products and services at booth 8.0H24 during CPHI, taking place in Frankfurt, Germany, from 28–30 October
Subscribe now